IL33 and systemic sclerosis: Indeed, IL-33 and its receptor ST2 are abnormally expressed in SSc and it has been postulated that in early SSc, IL-33 could be mobilized from areas of vascular damage to promote fibrosis in target organ through ST2 (18, 22) and the differentiation of Treg lymphocytes toward a Th2-like phenotype (23).